Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 5/20 | 0.44 |
| ▸ | CA1 | P00915 | 5/20 | 0.44 |
| ▸ | CA9 | Q16790 | 5/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.43 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20537232 | 0.88 | MTNR1A (0.53) | HPGDCA12CA1CA9MTNR1A | |
| SCHEMBL11580959 | 0.83 | NQO2 (0.50) | HPGDCA12CA1CA9MAPT | |
| SCHEMBL3822410 | 0.83 | CYP3A4 (0.49) | HPGDCA12CA1CA9MTNR1A | |
| SCHEMBL7650010 | 0.81 | CA12 (0.57) | HPGDCA12CA1CA9MTNR1A | |
| SCHEMBL13888301 | 0.81 | CA12 (0.44) | HPGDCA12CA1CA9MTNR1A | |
| SCHEMBL10591673 | 0.79 | CA12 (0.46) | HPGDCA12CA1CA9MTNR1A | |
| SCHEMBL14686064 | 0.79 | MAPT (0.51) | PLAUMTNR1AMAPTMEN1KMT2A | |
| SCHEMBL470906 | 0.78 | CA12 (0.57) | CA12CA1CA9MTNR1AMAPT | |
| SCHEMBL30541768 | 0.78 | CA12 (0.57) | CA12CA1CA9MTNR1AMAPT | |
| SCHEMBL26208605 | 0.77 | MTNR1A (0.42) | HPGDCA12CA1CA9MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108368069-B | Oxazine compound, composition and cured product | DIC株式会社 | 2022-10-14 | — | — | CN | disclosed |
| CN-108473642-B | Oxazine compound, composition and cured product | DIC株式会社 | 2021-05-07 | — | — | CN | disclosed |
| US-10913725-B2 | Oxazine compound, composition and cured product | DIC CORPORATION (JP) | 2021-02-09 | — | — | US | disclosed |
| US-10399312-B2 | Oxazine compound, composition and cured product | DIC CORPORATION (JP) | 2019-09-03 | — | — | US | disclosed |
| US-20180362479-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC CORPORATION (JP) | 2018-12-20 | — | — | US | disclosed |
| US-20180333941-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC CORPORATION (JP) | 2018-11-22 | — | — | US | disclosed |
| EP-3401311-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC Corporation (JP) | 2018-11-14 | — | — | EP | disclosed |
| EP-3392281-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC Corporation (JP) | 2018-10-24 | — | — | EP | disclosed |
| CN-108368069-A | Oxazine compound, composition and cured product | DIC株式会社 | 2018-08-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180333941-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | KDM5A, PSMB5, CUL5 | HPGD 1322/4885PLAU 4240/4885CA12 782/4885 |
| US-10913725-B2 | Oxazine compound, composition and cured product | PSMB5, KDM5A, CUL5 | HPGD 1165/4885PLAU 4138/4885CA12 974/4885 |
| US-20180362479-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | PSMB5, KDM5A, CUL5 | HPGD 1165/4885PLAU 4138/4885CA12 974/4885 |
| US-10399312-B2 | Oxazine compound, composition and cured product | KDM5A, PSMB5, CUL5 | HPGD 1322/4885PLAU 4240/4885CA12 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.